News
Higgins is an advocate for people with Li-Fraumeni syndrome. I was born with an inherited cancer syndrome, Li-Fraumeni syndrome (LFS). A mutation on my Tp53 cancer suppressor gene makes me ...
SELLAS Life Sciences Group, Inc. has announced promising preclinical results for SLS009, a selective CDK9 inhibitor, in treating TP53 mutated Acute Myeloid Leukemia (AML) cells, which typically ...
Patients with TP53–mutated AML continue to face extremely poor outcomes, even with intensive chemotherapy or the addition of stem cell transplantation. Preclinical data suggest that SLS009 ...
New Data Suggest SLS009 (tambiciclib) May Overcome Resistance to Azacitidine-Venetoclax Regimen and Trigger Apoptosis of TP53 Mutated AML Cells NEW YORK, April 28, 2025 (GLOBE NEWSWIRE) -- SELLAS Life ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results